冷链物流交流

首页 > 冷链物流交流

Bluebird IPO募集超1亿美元资金
发布时间：[2013/6/21]     访问人数：[1250]
 --专注罕见病基因疗法开发的Bluebird公司IPO以每股17美元的价格募集了超过1亿1百万美元的资金。就在几周前，Bluebird原本的募集计划定在7500万美元。此次IPO以后，Bluebird公司市场总价达到了3亿8千9百万美元。

详细英文报道：

Biotech IPOs are officially back in vogue. Bluebird bio--set up to develop new gene therapies for orphan diseases--priced its IPO at $17 a share, actually above its range. The biotech raised $101 million after bumping up the number of shares it had on offer.

Just a few weeks ago bluebird set its range at $14 to $16 a share, with plans to sell off 5 million shares with an eye to raising about $75 million in total. But it added nearly a million shares to the tally and bumped up the price, something that would have been almost unimaginable just a few months ago.

Regular readers of FierceBiotech should have no trouble recalling bluebird. The 2012 Fierce 15 company raised an estimated $134 million. The Third Rock creation--CEO Nick Leschly was part of the Millennium mafia that booted up the venture group--scored proof-of-concept data for adrenoleukodystrophy, or ALD. And then bluebird quickly shifted gears, focused on a late-stage study. The venture group that backs bluebird also includes Arch Venture Partners, Forbion Capital Partners, RA Capital Management, TVM Capital and some undisclosed investors. Third Rock owned 28% of the company ahead of the IPO.

At the current stock price, bluebird has a market value of about $389 million.

After the financial crisis of 2008, most general investors turned a cold should to biotech IPOs, unhappy with the heavy risk involved in drug development. That cold front lasted for 5 long years, creating problems for venture groups unable to cash out and forcing a general tightening of the money spigots, inspiring a far more austere budgeting process that forced everyone to get more focused on assets and lean staffs. But since the beginning of the year there's been a growing queue of biotechs lining up at the newly open IPO window, and bluebird's news is bound to inspire more such offerings.

Of course, now that the market has opened its arms to biotech, there's a growing fear that the go-go feeling won't last forever. Now the big question is how long this can last before the market turns sour again.